Bevacizumab-associated gastrointestinal perforation

The Lancet Oncology

Volumn 10, Issue 6, 2009, Pages 534-536

  Chau, Ian ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PROTON PUMP INHIBITOR;

AWARENESS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG USE; HEALTH CARE PERSONNEL; HUMAN; LETTER; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INTESTINAL PERFORATION;

EID: 66149117474     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70142-1     Document Type: Letter

References (12)

1. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
2. Hapani S., Chu D., and Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10 (2009) 559-568
3. Sugrue M., Kozloff M., Hainsworth J., et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. Proc Am Soc Clin Oncol 24 (2006) Abstr 3535.
4. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 (2006) 5201-5206
5. Crane C.H., Ellis L.M., Abbruzzese J.L., et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24 (2006) 1145-1151
6. Badgwell B.D., Camp E.R., Feig B., et al. Management of bevacizumab-associated bowel perforation: a case series and review of the literature. Ann Oncol 19 (2008) 577-582
7. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 (2007) 5180-5186
8. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 10.1093/annonc/mdp233 published online April 30.
9. Kozloff M.F., Sugrue M.M., Purdie D.M., et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BRiTE observational cohort study. Proc Am Soc Clin Oncol 26 (2008) 4026
10. Tol J., Cats A., Mol L., et al. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs 26 (2008) 393-397
11. Simpkins F., Belinson J.L., and Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107 (2007) 118-123
12. Allegra C.J., Yothers G., O'Connell M.J., et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol (2009) 10.1200/JCO.2009.21.9220 published online May 4.